Condition: Acute Lymphoblastic Leukemia, in Relapse · Acute Lymphoblastic Leukemia Refractory · B-cell Lymphoma Recurrent · Sponsor: Nelson Hamerschlak
This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).
This description comes directly from the study's public registry record.
Nelson Hamerschlak, MD, PhH · +551121517248 · hamer@einstein.br
Lucila N Kerbauy, MD, PhD · +5511998667557 · lucila.kerbauy@einstein.br
Always discuss trial participation with your own doctor first.
| Hospital Israelita Albert Einstein | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05705570